Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Schering-Plough’s Vytorin Headache Prove Contagious?

Executive Summary

The full impact of Schering-Plough's deepening woes after a scientific panel's negative analysis of the Vytorin ENHANCE trial will not be known for a while, and some analysts predict there could be repercussions beyond the company and its joint venture with Merck, a deal centered on the anti-cholesterol drug, which combines the statin Zocor (simvastatin) withZetia (ezetimibe)

You may also be interested in...



Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles

Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others

Merck Commercial Pilot Set To Fly Nationwide

Merck is rolling out a new commercial model, including a realigned sales organization, nationwide following a successful pilot program, Global Human Health President Kenneth Frazier said

Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles

Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others

Related Content

UsernamePublicRestriction

Register

PS049497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel